CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade AlloVir, Inc. - ALVR CFD

    0.72
    1.37%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026179 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026179%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003957 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003957%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Allovir Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 0.73
    Open* 0.73
    1-Year Change* -81.93%
    Day's Range* 0.71 - 0.73
    52 wk Range 0.62-7.24
    Average Volume (10 days) 2.96M
    Average Volume (3 months) 40.64M
    Market Cap 78.70M
    P/E Ratio -100.00K
    Shares Outstanding 114.06M
    Revenue N/A
    EPS -1.72
    Dividend (Yield %) N/A
    Beta 0.82
    Next Earnings Date Feb 13, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 17, 2024 0.73 0.02 2.82% 0.71 0.74 0.70
    Apr 16, 2024 0.71 -0.01 -1.39% 0.72 0.73 0.70
    Apr 15, 2024 0.72 -0.01 -1.37% 0.73 0.75 0.71
    Apr 12, 2024 0.74 0.00 0.00% 0.74 0.75 0.73
    Apr 11, 2024 0.75 0.02 2.74% 0.73 0.75 0.72
    Apr 10, 2024 0.72 -0.01 -1.37% 0.73 0.73 0.70
    Apr 9, 2024 0.72 0.02 2.86% 0.70 0.74 0.70
    Apr 8, 2024 0.72 -0.01 -1.37% 0.73 0.73 0.68
    Apr 5, 2024 0.73 -0.01 -1.35% 0.74 0.75 0.71
    Apr 4, 2024 0.74 -0.01 -1.33% 0.75 0.76 0.72
    Apr 3, 2024 0.74 0.00 0.00% 0.74 0.76 0.73
    Apr 2, 2024 0.74 -0.02 -2.63% 0.76 0.76 0.72
    Apr 1, 2024 0.78 0.04 5.41% 0.74 0.81 0.72
    Mar 28, 2024 0.74 0.01 1.37% 0.73 0.76 0.73
    Mar 27, 2024 0.74 0.01 1.37% 0.73 0.77 0.72
    Mar 26, 2024 0.73 0.02 2.82% 0.71 0.75 0.71
    Mar 25, 2024 0.73 -0.01 -1.35% 0.74 0.74 0.72
    Mar 22, 2024 0.73 0.00 0.00% 0.73 0.75 0.72
    Mar 21, 2024 0.74 0.02 2.78% 0.72 0.75 0.71
    Mar 20, 2024 0.72 0.01 1.41% 0.71 0.75 0.70

    AlloVir, Inc. Events

    Time (UTC) Country Event
    Thursday, May 2, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q1 2024 Allovir Inc Earnings Release
    Q1 2024 Allovir Inc Earnings Release

    Forecast

    -

    Previous

    -
    Friday, May 10, 2024

    Time (UTC)

    13:00

    Country

    US

    Event

    Allovir Inc Annual Shareholders Meeting
    Allovir Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Thursday, August 1, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q2 2024 Allovir Inc Earnings Release
    Q2 2024 Allovir Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0.165 1.135
    Revenue 0 0 0.165 1.135
    Total Operating Expense 171.202 169.818 71.309 26.866 4.731
    Selling/General/Admin. Expenses, Total 52.332 49.083 21.646 10.618 3.031
    Research & Development 118.87 120.735 49.663 16.248 1.7
    Operating Income -171.202 -169.818 -71.309 -26.701 -3.596
    Interest Income (Expense), Net Non-Operating 1.876 1.315 1.33 2.065 0.056
    Other, Net 0.351 -2.452 0.195 0.797 1.11
    Net Income Before Taxes -168.975 -170.955 -69.784 -23.839 -2.43
    Net Income After Taxes -168.71 -171.962 -69.784 -23.839 -2.43
    Net Income Before Extra. Items -168.71 -171.962 -69.784 -23.839 -2.43
    Net Income -168.71 -171.962 -69.784 -23.839 -2.43
    Total Adjustments to Net Income -5.726
    Income Available to Common Excl. Extra. Items -168.71 -171.962 -69.784 -23.839 -8.156
    Income Available to Common Incl. Extra. Items -168.71 -171.962 -69.784 -23.839 -8.156
    Diluted Net Income -168.71 -171.962 -69.784 -23.839 -8.156
    Diluted Weighted Average Shares 76.6549 62.7821 61.9313 69.1735 69.1735
    Diluted EPS Excluding Extraordinary Items -2.2009 -2.73903 -1.1268 -0.34463 -0.11791
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -2.2009 -2.73903 -1.1268 -0.34463 -0.11791
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 47.304 43.231 40.434 42.95 44.624
    Selling/General/Admin. Expenses, Total 12.48 12.513 12.014 12.946 13.245
    Research & Development 34.824 30.718 28.42 30.004 31.379
    Operating Income -47.304 -43.231 -40.434 -42.95 -44.624
    Interest Income (Expense), Net Non-Operating 1.516 1.325 0.898 0.668 0.162
    Other, Net 0.521 0.723 0.985 0.21 -0.027
    Net Income Before Taxes -45.267 -41.183 -38.551 -42.072 -44.489
    Net Income After Taxes -45.267 -41.183 -38.136 -42.072 -44.639
    Net Income Before Extra. Items -45.267 -41.183 -38.136 -42.072 -44.639
    Net Income -45.267 -41.183 -38.136 -42.072 -44.639
    Income Available to Common Excl. Extra. Items -45.267 -41.183 -38.136 -42.072 -44.639
    Income Available to Common Incl. Extra. Items -45.267 -41.183 -38.136 -42.072 -44.639
    Diluted Net Income -45.267 -41.183 -38.136 -42.072 -44.639
    Diluted Weighted Average Shares 94.6258 93.3037 92.9798 84.9488 64.4675
    Diluted EPS Excluding Extraordinary Items -0.47838 -0.44139 -0.41015 -0.49526 -0.69243
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.47838 -0.44139 -0.41015 -0.49526 -0.69243
    Revenue
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 243.052 253.348 361.317 127.313 25.313
    Cash and Short Term Investments 233.795 248.12 356.324 126.077 22.199
    Cash & Equivalents 106.092 201.661 122.661 61.084 22.199
    Short Term Investments 127.703 46.459 233.663 64.993 0
    Total Receivables, Net 0.157 0.05 0.45 0.56 0.302
    Accounts Receivable - Trade, Net 0 0.298 0.302
    Prepaid Expenses 9.1 5.178 4.543 0.676 0.051
    Other Current Assets, Total 0 2.761
    Total Assets 277.079 286.594 370.821 139.422 25.319
    Property/Plant/Equipment, Total - Net 32.563 31.292 9.504 12.109 0
    Other Long Term Assets, Total 1.464 1.954 0 0.006
    Total Current Liabilities 24.338 37.853 12.294 9.106 3.737
    Accounts Payable 3.004 8.361 0.963 0.63 0.153
    Accrued Expenses 21.15 26.743 10.759 8.23 0.674
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.184 2.749 0.572 0.246 2.91
    Total Liabilities 52.56 61.328 17.757 17.798 3.737
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 28.222 23.475 5.463 8.692 0
    Total Equity 224.519 225.266 353.064 121.624 21.582
    Redeemable Preferred Stock 0 0 0 173.127 52.204
    Common Stock 0.009 0.007 0.007 0 0
    Additional Paid-In Capital 690.753 522.479 478.272 3.748 0.858
    Retained Earnings (Accumulated Deficit) -465.775 -297.065 -125.103 -55.319 -31.48
    Unrealized Gain (Loss) 0.068 0
    Total Liabilities & Shareholders’ Equity 277.079 286.594 370.821 139.422 25.319
    Total Common Shares Outstanding 93.0932 63.5659 61.9313 69.1735 69.1735
    Property/Plant/Equipment, Total - Gross 33.567 31.573 9.596 12.128
    Accumulated Depreciation, Total -1.004 -0.281 -0.092 -0.019
    Other Equity, Total -0.468 -0.155 -0.112
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 220.019 252.912 212.275 243.052 272.042
    Cash and Short Term Investments 213.318 246.536 202.57 233.795 264.107
    Cash & Equivalents 95.627 196.954 115.698 106.092 123.834
    Short Term Investments 117.691 49.582 86.872 127.703 140.273
    Total Receivables, Net 0.234 0.106 0.244 0.157 0.261
    Prepaid Expenses 6.467 6.27 9.461 9.1 7.674
    Total Assets 248.312 282.692 244.044 277.079 293.698
    Property/Plant/Equipment, Total - Net 26.016 28.244 30.427 32.563 20.07
    Total Current Liabilities 33.066 30.563 24.959 24.338 20.719
    Accounts Payable 3.925 5.164 4.134 3.004 4.889
    Accrued Expenses 28.9 25.211 20.559 21.15 15.595
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.241 0.188 0.266 0.184 0.235
    Total Liabilities 52.978 53.579 50.512 52.56 40.472
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 19.912 23.016 25.553 28.222 19.753
    Total Equity 195.334 229.113 193.532 224.519 253.226
    Common Stock 0.011 0.011 0.009 0.009 0.009
    Additional Paid-In Capital 792.02 781.552 700.782 690.753 681.419
    Retained Earnings (Accumulated Deficit) -596.497 -552.225 -506.958 -465.775 -427.639
    Unrealized Gain (Loss)
    Total Liabilities & Shareholders’ Equity 248.312 282.692 244.044 277.079 293.698
    Total Common Shares Outstanding 113.967 113.716 93.428 93.0932 92.6401
    Other Long Term Assets, Total 2.277 1.536 1.342 1.464 1.586
    Other Equity, Total -0.2 -0.225 -0.301 -0.468 -0.563
    Redeemable Preferred Stock 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -168.71 -171.962 -69.784 -23.839 -2.43
    Cash From Operating Activities -142.052 -106.319 -60.811 -20.155 1.943
    Cash From Operating Activities 0.723 0.189 0.073 0.019 0
    Non-Cash Items 42.081 46.1 9.931 2.27 0.967
    Cash Interest Paid 0 0.125 0
    Changes in Working Capital -16.146 19.354 -1.031 1.395 3.406
    Cash From Investing Activities -80.478 185.983 -169.497 -64.644 0
    Capital Expenditures 0 -0.026 -0.235 -0.339 0
    Other Investing Cash Flow Items, Total -80.478 186.009 -169.262 -64.305 0
    Cash From Financing Activities 126.961 0.232 291.975 120.923 22.872
    Issuance (Retirement) of Stock, Net 126.961 0.232 295.449 120.923 22.872
    Net Change in Cash -95.569 79.852 61.577 36.124 24.815
    Financing Cash Flow Items 0 -3.474
    Foreign Exchange Effects 0 -0.044 -0.09
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -41.183 -168.71 -130.574 -88.502 -43.863
    Cash From Operating Activities -32.118 -142.052 -110.481 -75.354 -46.476
    Cash From Operating Activities 0.086 0.723 0.637 0.552 0.466
    Non-Cash Items 9.761 42.081 32.901 22.187 10.923
    Changes in Working Capital -0.782 -16.146 -13.445 -9.591 -14.002
    Cash From Investing Activities 41.724 -80.478 -94.015 -55.458 -54.979
    Capital Expenditures 0 0 0 0
    Other Investing Cash Flow Items, Total 41.724 -80.478 -94.015 -55.458 -54.979
    Foreign Exchange Effects 0 0 0 0
    Net Change in Cash 9.606 -95.569 -77.827 -130.568 -101.455
    Cash From Financing Activities 126.961 126.669 0.244 0
    Financing Cash Flow Items 0
    Issuance (Retirement) of Stock, Net 126.961 126.669 0.244
    Cash Taxes Paid 0

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    AlloVir, Inc. Company profile

    About Allovir Inc

    AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi- VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). Its LVR109 is an allogeneic VST therapy that targets severe acute respiratory syndrome coronavirus two (SARS-CoV-2).

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Allovir Inc revenues was not reported. Net loss increased from $69.8M to $172M. Higher net loss reflects Research and development increase from $46.1M to $100.1M (expense), Stock-based Compensation in SGA increase from $5.9M to $23.3M (expense), Stock-based Compensation in R&D increase from $3.6M to $20.6M (expense).

    Industry: Bio Therapeutic Drugs

    1100 Winter Street
    WALTHAM
    MASSACHUSETTS 02451
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

    Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

    07:56, 17 April 2024

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    A way forward: a roundup of recent central bank decisions

    Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

    12:47, 22 March 2024

    Bank of Japan Preview: will the BOJ end negative interest rates?

    The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

    08:44, 18 March 2024

    People also watch

    XRP/USD

    0.51 Price
    +2.210% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01168

    US100

    17,417.20 Price
    -0.440% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    ETH/USD

    3,063.63 Price
    +2.920% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 6.00

    BTC/USD

    63,345.30 Price
    +3.960% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading